Biotech

All Articles

Lilly, Haya ink $1B biobuck weight problems contract to explore darker genome

.Eli Lilly's search for being overweight aim ats has actually led it to the black genome. The Big Ph...

ArsenalBio increases $325M, turns out of former lead asset

.Arsenal Biosciences is actually carrying on up. The cell therapy business has added $325 thousand i...

Lilly- backed weight reduction biotech reports IPO

.After elevating $170 thousand back in February, metabolic disease-focused BioAge Labs has actually ...

Aelis' marijuana usage medicine fails phase 2b, driving Indivior to reconsider $100M possibility

.Aelis Farma's hopes of getting an easy, positive choice on a $100 million possibility remittance ha...

ProKidney halts phase 3 trial certainly not required for cell therapy approval

.ProKidney has ceased one of a set of stage 3 trials for its own tissue therapy for renal illness af...

Vaxcyte rises on 'magnificent' 31-valent PCV gain versus Pfizer

.Vaxcyte unveiled what professionals named "sensational" phase 1/2 data for its own 31-valent pneumo...

Recursion's human brain disease test shows scant documentation of effectiveness

.Recursion has discovered through an early examination of its own tech-enabled method to medication ...

Acepodia, Pfizer click together for chemistry-based cell therapy

.Call it a scenario of excellent chemical make up: Acepodia, a biotech based upon Nobel Prize-winnin...

Praxis epilepsy medicine minimizes confiscations in phase 2 litigation

.Practice Accuracy Medicines has actually scored another midphase gain in epilepsy this year, along ...

Three execs surrender as Dyne messages mixed information for DMD prospect

.After leaving a scientific grip several years back, Dyne Rehab has actually uncovered brand new pha...